Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (323)	8/11/2003 4:27:52 PM
From: Ian@SI	Read Replies (2) \| Respond to of 824

Re your comment to MJ: You are right on all counts and in principle Perhaps not on all counts. You may recall that ALXN quit talking to the investment community when it overreacted to one of its conference calls. At that time I believe Lenny stated that he preferred to present results to the scientific community which may be better able to interpret the data presented. At least this time, he held a conference call which was available to the general public. Now if we can only get Webcasts - both live and replays. And we still have Pex reducing deaths without introducing adverse side effects. Personally I have a hard time believing that the FDA will say, "Let's do some more trials. Who cares how many pts die needlessly while we figure out whether it's 26% of those deaths or 31% of them which could and should have been avoided." The leaderless FDA might have behaved in that fashion. I don't think it would be consistent with McLelland's approach. JMO, Ian